CIB1 and triple-negative breast carcinoma: 39 Thus, combination therapy targeting CIB1 may prove to be a safe and durable strategy for treating triple-negative breast cancer and potentially other cancers.39 Our research highlights the value of CIB1 blockade as an effective candidate to overcome HCC resistance to lenvatinib.